A real-world UK study shows that durvalumab following chemoradiotherapy effectively extends overall and progression-free ...
Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line ...
MedPage Today on MSN
'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC
B ERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or ...
Balazs Halmos, MD, discussed the potential impact of subcutaneous amivantamab for patients with EGFR -mutated NSCLC. Halmos ...
After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...
Immutep (IMMP) announces two poster presentations at the European Society for Medical Oncology Congress 2025 highlight the Company’s focus on ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...
Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC: Ingelheim, Germany Monday, Oc ...
Dr Mark Kris continues his discussion on neoadjuvant vs adjuvant therapy for locally advanced lung cancer, offering his take ...
Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback